Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Randomized Double-blind Placebo-controlled Study of Tezacaftor/Ivacaftor in Orkambi-experienced F508del Homozygous Cystic Fibrosis Patients
2017-000540-18Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing TEZ/IVA with Placebo (2 arms). Primary endpoint: Incidence of respiratory adverse events. Started Aug 2017; status: completed.
02
Drugs
tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-000540-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000540-18.